News | Proton Therapy | November 21, 2017

Mevion Achieves CE Mark for S250i Proton Therapy System

First European install of next-generation pencil beam scanning therapy system scheduled for 2018 completion

Mevion Achieves CE Mark for S250i Proton Therapy System

November 21, 2017 — Mevion Medical Systems announced the Mevion S250i Proton Therapy System has achieved CE Marking clearance. CE Marking permits clinical use of the system within the European Union and any country that recognizes the CE Mark. The system includes Hyperscan technology, the next generation of pencil beam scanning (PBS) for faster, sharper and more robust proton treatments.

European CE Marking is the first regulatory clearance for the Mevion S250i. Mevion also submitted for U.S. Food and Drug Administration (FDA) 510(k) clearance in September.

The first European S250i proton therapy system installation will be completed in 2018 at the Zuid-Oost Nederland Protonen Therapie Centrum (ZON PTC) at the Maastro Clinic in Maastricht, the Netherlands. The system will be the first of its kind in Europe. The Hyperscan PBS technology incorporates the fastest energy layer switching, optimized spot sizes and the Adaptive Aperture proton multi-leaf collimator system. This capability provides dose gradient advantages with up to a three times sharper lateral penumbra, reducing dose uncertainty at the edge of the tumor, thus sparing healthy tissue and preventing unnecessary radiation to sensitive locations. This improved precision in delivery is combined with hyper-fast beam delivery, reducing the sensitivity to motion that current PBS technologies face when treating moving lesions such as those in the thoracic cavity.

The S250i system is based on Mevion’s high-efficiency, low-financial-risk S250 Series platform. The core technology of the S250 Series includes what the company calls the world’s only gantry mounted superconducting synchrocyclotron, a six degree-of-freedom treatment couch and advanced in-room image-guided radiation therapy (IGRT), all leveraged in the S250i system.

The Mevion S250i lowers the cost per patient by reducing capital and operating costs and increasing treatment throughput. Mevion customers have achieved the fastest per-room patient ramp-up in the history of proton therapy, according to the company. High throughput is achieved via linear accelerator (linac)-like workflow, low maintenance requirements and high uptime.

For more information: www.mevion.com

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init